Enigma of IL-17 and Th17 cells in rheumatoid arthritis and in autoimmune animal models of arthritis

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Kugyelka, Reka ^a   Kohl, Zoltan ^a   Olasz, Katalin ^a   Mikecz, Katalin ^b   Rauch, Tibor A ^b   Glant, Tibor T ^b   Boldizsar, Ferenc ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; PROTEOGLYCAN;

ARTICLE; AUTOIMMUNITY; HUMAN; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RODENT MODEL; TH1 CELL; TH17 CELL; ANIMAL; AUTOIMMUNE DISEASE; DISEASE MODEL; IMMUNOLOGY; METABOLISM;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-17; TH17 CELLS;

EID: 84958781295     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/6145810     Document Type: Article

References (88)

1. D. L. Scott, F. Wolfe, and T. W. J. Huizinga, "Rheumatoid arthritis, " The Lancet, vol. 376, no. 9746, pp. 1094-1108, 2010.
2. A. J. Landré-Beauvais, "The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800, " Joint Bone Spine, vol. 68, no. 2, pp. 130-143, 2001.
3. G. Azizi, F. Jadidi-Niaragh, and A. Mirshafiey, "Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis, " International Journal of Rheumatic Diseases, vol. 16, no. 3, pp. 243-253, 2013.
4. M. Schiff, "Abatacept treatment for rheumatoid arthritis, " Rheumatology, vol. 50, no. 3, pp. 437-449, 2011.
5. S. P. Singh, H. H. Zhang, J. F. Foley, M. N. Hedrick, and J. M. Farber, "Human T cells that are able to produce IL-17 express the chemokine receptor CCR6, " Journal of Immunology, vol. 180, no. 1, pp. 214-221, 2008.
6. E. V. Acosta-Rodriguez, G. Napolitani, A. Lanzavecchia, and F. Sallusto, "Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells, " Nature Immunology, vol. 8, no. 9, pp. 942-949, 2007.
7. E. Segura, M. Touzot, A. Bohineust et al., "Human inflammatory dendritic cells induce Th17 cell differentiation, " Immunity, vol. 38, no. 2, pp. 336-348, 2013.
8. J. P. van Hamburg, P. S. Asmawidjaja, N. Davelaar et al., "Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production, " Arthritis & Rheumatism, vol. 63, no. 1, pp. 73-83, 2011.
9. S. M. J. Paulissen, J. P. van Hamburg, W. Dankers, and E. Lubberts, "The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis, " Cytokine, vol. 74, no. 1, pp. 43-53, 2015.
10. L. G. M. van Baarsen, M. C. Lebre, D. van der Coelen et al., "Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?" Arthritis Research & Therapy, vol. 16, no. 4, article 426, 2014.
11. G. Zizzo, M. De Santis, S. L. Bosello et al., "Synovial fluidderived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis, " Clinical Immunology, vol. 138, no. 1, pp. 107-116, 2011.
12. Y. Kondo, Z. Yao, M. Tahara et al., "Involvement of RORγt overexpressing T cells in the development of autoimmune arthritis in mice, " Arthritis Research & Therapy, vol. 17, no. 1, 2015.
13. K. Hirota, H. Yoshitomi, M. Hashimoto et al., "Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model, " Journal of Experimental Medicine, vol. 204, no. 12, pp. 2803-2812, 2007.
14. E. Rouvier, M.-F. Luciani, M.-G. Mattei, F. Denizot, and P. Golstein, "CTLA-8, cloned from an activated T cell, bearing AUrich messenger RNA instability sequences, and homologous to a herpesvirus Saimiri gene, "The Journal of Immunology, vol. 150, no. 12, pp. 5445-5456, 1993.
15. Z. Yao, W. C. Fanslow, M. F. Seldin et al., "Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor, " Immunity, vol. 3, no. 6, pp. 811-821, 1995.
16. F. Fossiez, O. Djossou, P. Chomarat et al., "T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines, " Journal of Experimental Medicine, vol. 183, no. 6, pp. 2593-2603, 1996.
17. J. Kennedy, D. L. Rossi, S. M. Zurawski et al., "Mouse IL-17: a cytokine preferentially expressed by αβTCR+CD4-CD8-T cells, " Journal of Interferon & Cytokine Research, vol. 16, no. 8, pp. 611-617, 1996.
18. T. R. Mosmann, H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman, "Two types ofmurine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins, " The Journal of Immunology, vol. 136, no. 7, pp. 2348-2357, 1986.
19. L. H. Glimcher and K. M. Murphy, "Lineage commitment in the immune system: the T helper lymphocyte grows up, " Genes and Development, vol. 14, no. 14, pp. 1693-1711, 2000.
20. L. Steinman, "A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage, " Nature Medicine, vol. 13, no. 2, pp. 139-145, 2007.
21. C. Infante-Duarte, H. F. Horton, M. C. Byrne, and T. Kamradt, "Microbial lipopeptides induce the production of IL-17 in Th cells, " Journal of Immunology, vol. 165, no. 11, pp. 6107-6115, 2000.
22. S. L. Gaffen, J. M. Kramer, J. J. Yu, and F. Shen, "The IL-17 cytokine family, "Vitamins and Hormones, vol. 74, pp. 255-282, 2006.
23. C. Gu, L. Wu, and X. Li, "IL-17 family: cytokines, receptors and signaling, " Cytokine, vol. 64, no. 2, pp. 477-485, 2013.
24. W. Ouyang, J. K. Kolls, and Y. Zheng, "The biological functions of T helper 17 cell effector cytokines in inflammation, " Immunity, vol. 28, no. 4, pp. 454-467, 2008.
25. M. Chabaud, J. M. Durand, N. Buchs et al., "Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium, " Arthritis and Rheumatism, vol. 42, no. 5, pp. 963-970, 1999.
26. R. Florencio-Silva, G. R. da Sasso, E. Sasso-Cerri, M. J. Simões, and P. S. Cerri, "Biology of bone tissue: structure, function, and factors that influence bone cells, " BioMed Research International, vol. 2015, Article ID 421746, 17 pages, 2015.
27. S. M. Jung, K. W. Kim, C.-W. Yang, S.-H. Park, and J. H. Ju, "Cytokine-mediated bone destruction in rheumatoid arthritis, " Journal of Immunology Research, vol. 2014, Article ID263625, 15 pages, 2014.
28. T. Dimitroulas, S. N. Nikas, P. Trontzas, and G. D. Kitas, "Biologic therapies and systemic bone loss in rheumatoid arthritis, " Autoimmunity Reviews, vol. 12, no. 10, pp. 958-966, 2013.
29. K.-W. Kim, H.-R. Kim, B.-M. Kim, M.-L. Cho, and S.-H. Lee, "Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis, " The American Journal of Pathology, vol. 185, no. 11, pp. 3011-3024, 2015.
30. S. Kotake, N. Udagawa, N. Takahashi et al., "IL-17 in synovial fluids frompatients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, "The Journal of Clinical Investigation, vol. 103, no. 9, pp. 1345-1352, 1999.
31. M. Chabaud, E. Lubberts, L. Joosten, W. van Den Berg, and P. Miossec, "IL-17 derived from juxta-articular bone and synoviumcontributes to joint degradation in rheumatoid arthritis, " Arthritis Research, vol. 3, no. 3, pp. 168-177, 2001.
32. I. E. Adamopoulos, C.-C. Chao, R. Geissler et al., "Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors, " Arthritis Research and Therapy, vol. 12, no. 1, article R29, 2010.
33. N. Caccamo, C. LaMendola, V. Orlando et al., "Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells, " Blood, vol. 118, no. 1, pp. 129-138, 2011.
34. E. C. Keystone, C. Rittershaus, N. Wood et al., "Elevation of a gamma deltaTcell subset inperipheral bloodand synovial fluid of patients with rheumatoid arthritis, " Clinical and Experimental Immunology, vol. 84, no. 1, pp. 78-82, 1991.
35. Y. Ito, T. Usui, S. Kobayashi et al., "Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis, " Arthritis & Rheumatism, vol. 60, no. 8, pp. 2294-2303, 2009.
36. A. Pappalardo and K. Thompson, "Activated γδ T cells inhibit osteoclast differentiation and resorptive activity in vitro, " Clinical and Experimental Immunology, vol. 174, no. 2, pp. 281-291, 2013.
37. + γδ T cells, drive arthritic bone destruction in mice and humans, " The Journal of Immunology, vol. 186, no. 4, pp. 2602-2612, 2011.
38. K. Hirota, M. Hashimoto, H. Yoshitomi et al., "T cell selfreactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis, " Journal of Experimental Medicine, vol. 204, no. 1, pp. 41-47, 2007.
39. J. Duarte, A. Agua-Doce, V. G. Oliveira, J. E. Fonseca, and L. Grac, "Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice, " PLoS ONE, vol. 5, no. 5, Article IDe10558, 2010.
40. A. Shiomi, T. Usui, Y. Ishikawa, M. Shimizu, K. Murakami, and T. Mimori, "GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice, " Journal of Immunology, vol. 193, no. 2, pp. 849-859, 2014.
41. H.-J. Wu, I. I. Ivanov, J. Darce et al., "Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells, " Immunity, vol. 32, no. 6, pp. 815-827, 2010.
42. M. Katayama, K. Ohmura, N. Yukawa et al., "Neutrophils are essential as a source of IL-17 in the effector phase of arthritis, " PLoS ONE, vol. 8, no. 5, Article ID e62231, 2013.
43. C. D. Sadik, N. D. Kim, E. Alekseeva, and A. D. Luster, "Il-17RA signaling amplifies antibody-induced arthritis, " PLoS ONE, vol. 6, no. 10, Article ID e26342, 2011.
44. S. R. Pickens, M. V. Volin, A. M. Mandelin II, J. K. Kolls, R. M. Pope, and S. Shahrara, "IL-17 contributes to angiogenesis in rheumatoid arthritis, " Journal of Immunology, vol. 184, no. 6, pp. 3233-3241, 2010.
45. S. Nakae, S. Saijo, R. Horai, K. Sudo, S. Mori, and Y. Iwakura, "IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5986-5990, 2003.
46. M.-J. Park, H.-S. Park, H.-J. Oh et al., "IL-17-deficient allogeneic bone marrow transplantation prevents the induction of collagen-induced arthritis in DBA/1J mice, " Experimental and Molecular Medicine, vol. 44, no. 11, pp. 694-705, 2012.
47. E. Lubberts, M. I. Koenders, B. Oppers-Walgreen et al., "Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion, " Arthritis and Rheumatism, vol. 50, no. 2, pp. 650-659, 2004.
48. J. Qi, F. Kan, X. Ye et al., "A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis, " International Immunopharmacology, vol. 14, no. 4, pp. 770-778, 2012.
49. Y. Zhang, G. Ren, M. Guo et al., "Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model, " International Immunopharmacology, vol. 15, no. 2, pp. 199-205, 2013.
50. Q. Li, G. Ren, L. Xu et al., "Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model, " International Immunopharmacology, vol. 21, no. 1, pp. 119-127, 2014.
51. A. E. M. van Nieuwenhuijze, F. A. van de Loo, B. Walgreen et al., "Complementary action of granulocytemacrophage colonystimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis, " Arthritis Research & Therapy, vol. 17, article 163, no. 1, 2015.
52. Y. Yamaguchi, K. Fujio, H. Shoda et al., "IL-17B and IL-17C are associated with TNF-α production and contribute to the exacerbation of inflammatory arthritis, " The Journal of Immunology, vol. 179, no. 10, pp. 7128-7136, 2007.
53. C. L. Roark, Y. Huang, N. Jin et al., "A canonical Vγ4Vδ4+ γδ T cell population with distinct stimulation requirements which promotes theTh17 response, " Immunologic Research, vol. 55, no. 1-3, pp. 217-230, 2013.
54. H. Ogura, M. Murakami, Y. Okuyama et al., "Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction, " Immunity, vol. 29, no. 4, pp. 628-636, 2008.
55. M. Fujimoto, S. Serada, M. Mihara et al., "Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses, " Arthritis and Rheumatism, vol. 58, no. 12, pp. 3710-3719, 2008.
56. K. Sato, A. Suematsu, K. Okamoto et al., "Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction, " The Journal of Experimental Medicine, vol. 203, no. 12, pp. 2673-2682, 2006.
57. E. Lubberts, L. A. B. Joosten, M. Chabaud et al., "IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion, " Journal of Clinical Investigation, vol. 105, no. 12, pp. 1697-1710, 2000.
58. C. A. Murphy, C. L. Langrish, Y. Chen et al., "Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation, " Journal of Experimental Medicine, vol. 198, no. 12, pp. 1951-1957, 2003.
59. S. R. Pickens, N. D. Chamberlain, M. V. Volin et al., "Local expression of interleukin-27 ameliorates collagen-induced arthritis, " Arthritis and Rheumatism, vol. 63, no. 8, pp. 2289-2298, 2011.
60. L. Ye, B. Jiang, J. Deng et al., "IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation, " The Journal of Immunology, vol. 194, no. 11, pp. 5110-5119, 2015.
61. C. K. C. Lo, Q. L. K. Lam, L. Sun et al., "Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production, " Arthritis and Rheumatism, vol. 58, no. 9, pp. 2700-2711, 2008.
62. N. A. Carter, E. C. Rosser, and C. Mauri, "Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis, " Arthritis Research and Therapy, vol. 14, no. 1, article R32, 2012.
63. J. Tao, M. Kamanaka, J. Hao et al., "IL-10 signaling in CD4+ T cells is critical for the pathogenesis of collagen-induced arthritis, " Arthritis Research and Therapy, vol. 13, no. 6, article R212, 2011.
64. R. A. Ratsimandresy, E. Duvallet, E. Assier et al., "Active immunization against IL-23p19 improves experimental arthritis, " Vaccine, vol. 29, no. 50, pp. 9329-9336, 2011.
65. K. Vermeire, H. Heremans, M. Vandeputte, S. Huang, A. Billiau, and P. Matthys, "Accelerated collagen-induced arthritis in IFNgamma receptor-deficient mice, " The Journal of Immunology, vol. 158, no. 11, pp. 5507-5513, 1997.
66. H. Kelchtermans, E. Schurgers, L. Geboes et al., "Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-γ and counteraction by interferon-γ, " Arthritis Research and Therapy, vol. 11, no. 4, article R122, 2009.
67. A. Finnegan, M. J. Grusby, C. D. Kaplan et al., "IL-4 and IL-12 regulate proteoglycan-induced arthritis through stat-dependent mechanisms, " Journal of Immunology, vol. 169, no. 6, pp. 3345-3352, 2002.
68. P. D. Doodes, Y. Cao, K. M. Hamel et al., "Development of proteoglycan-induced arthritis is independent of IL-17, "TheJournal of Immunology, vol. 181, no. 1, pp. 329-337, 2008.
69. P. D. Doodes, Y. Cao, K. M. Hamel et al., "IFN-γ regulates the requirement for IL-17 in proteoglycan-induced arthritis, " Journal of Immunology, vol. 184, no. 3, pp. 1552-1559, 2010.
70. W. Hueber, D. D. Patel, T. Dryja et al., "Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis, " Science Translational Medicine, vol. 2, no. 52, Article ID 52ra72, 2010.
71. M. C. Genovese, P. Durez, H. B. Richards et al., "Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study, " Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 863-869, 2013.
72. M. C. Genovese, P. Durez, H. B. Richards et al., "One-year efficacy and safety results of secukinumab in patientswith rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study, " Journal of Rheumatology, vol. 41, no. 3, pp. 414-421, 2014.
73. M. C. Genovese, F. Van den Bosch, S. A. Roberson et al., "LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proofof-concept study, " Arthritis and Rheumatism, vol. 62, no. 4, pp. 929-939, 2010.
74. M. C. Genovese, M. Greenwald, C.-S. Cho et al., "A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors, " Arthritis & Rheumatology, vol. 66, no. 7, pp. 1693-1704, 2014.
75. D. A. Martin, M. Churchill, L. F. Flores-Suarez et al., "A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis, " Arthritis Research and Therapy, vol. 15, no. 5, article R164, 2013.
76. K. Pavelka, Y. Chon, R. Newmark, S.-L. Lin, S. Baumgartner, and N. Erondu, "A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate, " The Journal of Rheumatology, vol. 42, no. 6, pp. 912-919, 2015.
77. N. Sakaguchi, T. Takahashi, H. Hata et al., "Altered thymic Tcell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice, " Nature, vol. 426, no. 6965, pp. 454-460, 2003.
78. V. Kouskoff, A.-S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis, "Organ-specific disease provoked by systemic autoimmunity, " Cell, vol. 87, no. 5, pp. 811-822, 1996.
79. I. I. Ivanov, R. D. L. Frutos, N. Manel et al., "Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine, " Cell Host and Microbe, vol. 4, no. 4, pp. 337-349, 2008.
80. S. Nakae, A. Nambu, K. Sudo, and Y. Iwakura, "Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice, " Journal of Immunology, vol. 171, no. 11, pp. 6173-6177, 2003.
81. S. Sarkar, L. A. Tesmer, V. Hindnavis, J. L. Endres, and D. A. Fox, "Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4, " Arthritis and Rheumatism, vol. 56, no. 1, pp. 89-100, 2007.
82. F. Boldizsar, O. Tarjanyi, P. Nemeth, K. Mikecz, and T. T. Glant, "Th1/Th17 polarization and acquisition of an arthritogenic phenotype in arthritis-susceptible BALB/c, but not in MHCmatched, arthritis-resistant DBA/2 mice, " International Immunology, vol. 21, no. 5, pp. 511-522, 2009.
83. T. T. Glant, K. Mikecz, A. Arzoumanian, and A. R. Poole, "Proteogly can-induced arthritis in BALB/c mice. Clinical features and histopathology, " Arthritis and Rheumatism, vol. 30, no. 2, pp. 201-212, 1987.
84. T. T. Glant, A. Finnegan, and K. Mikecz, "Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics, " Critical Reviews in Immunology, vol. 23, no. 3, pp. 199-250, 2003.
85. A. Finnegan, K. Mikecz, P. Tao, and T. T. Glant, "Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated byTh2cytokines, " The Journal of Immunology, vol. 163, no. 10, pp. 5383-5390, 1999.
86. K. Papp, C. Leonardi, A. Menter et al., "Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment, " Journal of the American Academy of Dermatology, vol. 71, no. 6, pp. 1183-1190. e3, 2014.
87. P. Miossec and J. K. Kolls, "Targeting IL-17 and TH17 cells in chronic inflammation, " Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 763-776, 2012.
88. I. B. McInnes, J. Sieper, J. Braun et al., "Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase ii proof-of-concept trial, " Annals of the Rheumatic Diseases, vol. 73, no. 2, pp. 349-356, 2014.